PTC Therapeutics: Translarna Setback & What’s Next for the Stock?
Berlin – A significant setback for PTC Therapeutics as the company has withdrawn its Modern Drug Application (NDA) resubmission for Translarna (ataluren) in the United States. The decision, announced on February 12, 2026, follows feedback from the U.S. Food and Drug Administration (FDA) indicating that the data supporting the application were unlikely to demonstrate substantial … Read more